RxSight, Inc. (NASDAQ:RXST) Shares Sold by Sei Investments Co.

Sei Investments Co. reduced its stake in RxSight, Inc. (NASDAQ:RXST – Free Report) by 9.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,681 shares of the company’s stock after selling 5,205 shares during the period. Sei Investments Co. owned 0.14% of RxSight worth $3,109,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Amalgamated Bank grew its position in shares of RxSight by 21.3% in the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after acquiring an additional 207 shares in the last quarter. Crossmark Global Holdings Inc. raised its stake in shares of RxSight by 3.2% in the second quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company’s stock valued at $473,000 after buying an additional 242 shares during the period. RiverPark Advisors LLC boosted its holdings in shares of RxSight by 9.6% during the second quarter. RiverPark Advisors LLC now owns 3,379 shares of the company’s stock valued at $203,000 after purchasing an additional 297 shares in the last quarter. CWM LLC boosted its position in shares of RxSight by 727.5% in the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after buying an additional 371 shares during the period. Finally, Arizona State Retirement System boosted its holdings in RxSight by 5.0% in the second quarter. Arizona State Retirement System now owns 7,765 shares of the company’s stock worth $467,000 after buying an additional 373 shares during the last quarter. 78.78% of shares are owned by institutional investors and hedge funds.

Insider trading at RxSight

In other RxSight news, insider Ilya Goldshleger sold 9,000 shares of the business’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $39.25, for a total transaction of $353,250.00. Following the completion of the sale, the insider now directly owns 42,246 shares of the company’s stock, valued at $1,658,155.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available via this link. Insiders have sold 21,405 shares of company stock worth $986,423 in the last three months. Company insiders own 9.36% of the company’s shares.

RxSight Price Performance

Shares of RXST opened at $47.85 on Friday. The company’s 50-day moving average is $51.16 and its 200-day moving average is $53.86. RxSight, Inc. has a 12-month low of $20.66 and a 12-month high of $66.54. The stock has a market cap of $1.77 billion, a P/E ratio of -37.98 and a beta of 1.20.

RxSight (NASDAQ:RXST – Get Your Free Report ) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.06. The company had revenue of $34.89 million for the quarter, compared to analysts’ expectations of $32.33 million. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The company’s revenue increased by 67.6% year-on-year. In the same quarter last year, the company earned ($0.40) earnings per share. As a group, equities research analysts forecast that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

Analysts on Wall Street are forecasting an increase

A number of research analysts have issued reports on the company. Wells Fargo & Company cut their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Stifel Nicolaus decreased their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. BTIG Research boosted their price objective on shares of RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a report on Monday, July 15th. Finally, Oppenheimer decreased their price objective on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Seven research analysts have rated the stock with a buy rating. RxSight has an average rating of “Buy” and a consensus price target of $60.14, according to MarketBeat.

Check out the latest stock analysis on RXST

RxSight Company Profile

(Free Report)

RxSight, Inc, a commercial medical device company, engages in the research and development, manufacture and sale of adjustable light intraocular lenses (LAL) used in cataract surgery in the United States and internationally. Offers the RxSight system that allows doctors to customize and improve patients’ visual acuity after cataract surgery.

Featured stories

Get news and reviews for RxSight Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for RxSight and related companies with MarketBeat.com’s FREE daily email newsletter.